Article
CCR6 and CCL20: emerging players in the pathogenesis of rheumatoid arthritis.
Immunology and cell biology - 1 Apr 2014
Lee Adrian Y S, Körner Heinrich
Abstract excerpt
The therapeutic targeting of pro-inflammatory TNF with neutralising biological anti-TNF agents, often in combination with other disease-modifying anti-rheumatic drugs, such as the purine synthesis inhibitor methotrexate has been the first major break-through in the treatment of chronic inflammatory diseases in decades. There are however, side effects and disadvantages of these treatments, such as general...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
